Jan 22-25, 2019

Tuesday - Friday

Germantown, MD

The Bioscience Education Center


1 Hour Lunch Break

This four-day workshop is ideal for researchers interested in developing neural lineages from iPSCs. Team taught by active researchers from Johns Hopkins, the NIH, the FDA, and Thermo Fisher Scientific, participants will have the opportunity to gain a solid foundation in iPSC methods with emphasis on deriving iPSC and differentiating to different neural lineage. Functional assays will be discussed in lectures for assessing neuronal differentiation. Applications of Neural derived IPSC will be discussed to neuropharmacology, toxicity testing, and therapy.

Lecture and Hands-on Interactive Training
Team taught by active researchers
Comprehensive binder containing workshop material
Space limited to 24 participants
Registration Fee: $995

Workshop Sponsor

Course Director

Course Director Photo

Joseph Bressler, Ph.D.
Research Scientist, Kennedy Krieger Institute

• Introduction to Mouse and Human Induced Pluripotent Stem Cells
• Overview of Cellular Reprogramming Methodologies
• mRNA Reprogramming of Patient Sample
• Deriving IPSc from Blood Cells
• Neural Differentiation Methods
• Neurons from IPSC into Model Mental Illnesses
• Using Neurons Derived from IPSc in Electrophysiology
• Application of iPSCs for Toxicology in the 21st Century
• FDA Regulation of Induced Pluripotent Stem Cell Based Products
  • Review of primary human iPSC cultures
  • Live-staining of primary mRNA iPSC colonies
  • Picking human mRNA iPSC colonies
  • Staining mRNA iPSCs for Alkaline Phosphatase Activity
  • Maintenance of high-quality PSCs: Passaging PSCs in a feeder-free culture system; Grooming techniques to remove spontaneous differentiation
  • Neural induction of PSCs (Part I): Harvesting and plating cells; Expanding P0 NSCs
  • Cryopreservation of NSCs
  • Neural induction of PSCs (Part II): Maintenance of cultures from Day 1
  • PSC Differentiation into Dopaminergic Neurons (Part I): Harvesting and plating cells for differentiation (Day 0); Passaging Floor plate progenitors for expansion (Day 10); Floor plate sphere dissociation for maturation
  • ICC of Neuronal Progenitors (Part I): Blocking and addition of primary antibodies
  • PSC Differentiation into Dopaminergic Neurons (Part II): Maintenance of cultures from Day 2
  • ICC of Neuronal Progenitors (Part II): Addition of secondary antibodies; Imaging

Course Director

Dr. Joseph Bressler is a research scientist at Kennedy Krieger Institute. He is also an associate professor of environmental health sciences at the Bloomberg School of Public Health at Johns Hopkins University.

Dr. Bressler received his bachelor's of science degree in biology from the State University of New York at Stony Brook in 1973 and his doctoral degree in physiology from Rutgers University in 1978. His post-doctoral training at UCLA was in neurosciences, where he studied the involvement of glial cells in response to toxic agents. After his post-doctoral training, Dr. Bressler continued his studies on glial cells at the National Institutes of Health, Bethesda, MD. Dr. Bressler has been a research scientist at the Kennedy Krieger Institute since 1988. 

Guest Lecturers and Lab Instructors

David M. Panchision, Ph.D.
David Panchision is the Chief of the Developmental Neurobiology Program at the National Institute of Mental Health. Dr. Panchision coordinates funding initiatives for the use of induced pluripotent stem cells (iPSCs) to study mental illness. He is Science Officer overseeing several cooperative agreements related to the use of iPSCs, including academic-industry partnerships (PAR-13-225) to use iPSCs to develop validated platforms for identifying novel targets and developing new therapeutics to treat mental illness. Prior to joining NIMH, he was Assistant Professor at Children’s National Medical Center and George Washington University in Washington, DC, where his research focused on the interaction between morphogen and oxygen response signaling in both normal neural stem cells and patient‐derived brain cancer stem cells.
Donald W. Fink, Jr., Ph.D.
Dr. Donald Fink is in the Cell Therapy Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), FDA. He possesses over 20-years of regulatory review experience evaluating applications for a diversity of products including cell-based therapies, recombinant proteins, monoclonal antibody-based reagents, therapeutic vaccines, medical devices used for collection of cellular blood components, cell selection, or preparation of autologous cellular grafts; and combination products.
Presently, Dr. Fink is engaged in regulatory activities pertaining to investigational products comprised of or derived from stem cells. He oversees an extensive portfolio of applications that includes hematopoietic, mesenchymal, cord blood, placenta-derived, and pluripotent stem cell-derived cellular products.
Alexandria Sams, Ph.D.
Dr. Alexandria Sams completed her doctoral thesis in Dr. Linda Griffith’s lab at the Massachusetts Institute of Technology. Her research focused on developing a three-dimensional liver model to study hepatitis B viral infection. She joined Life Technologies (now part of Thermo Fisher) in 2008 as a Staff Scientist where she developed multiple media and matrices for pluripotent stem cell culture (e.g., Essential 6™, Vitronectin, MEF). Dr. Sams manages the Gibco™ Stem Cell Research Center that offers multiple workshops throughout the year to provide hands-on training for customers interested in different aspects of the stem cell workflow (e.g., reprogramming, culture, characterization, editing, differentiation).
Tea Soon Park, Ph.D.
Dr. Park is a Research Associate at Division of Pediatric Oncology and Institute for Cell Engineering, Johns Hopkins School of Medicine. Foundation of her researches is on generation of clinically relevant human induced pluripotent stem cells (iPSC), differentiation of human pluripotent stem cells (hPSC) into hemato-vascular lineage and enhancement of functional pluripotency using naïve reversion method. Using these technologies, her current research focuses on treatment of ischemic damages (e.g. ischemic retinopathy) and diabetic vascular complications with iPSC derived progenitor cells.

The Bioscience Education Center

Montgomery College
20200 Observation Drive
Germantown, MD 20876